230 related articles for article (PubMed ID: 21931860)
21. Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.
Mayer-Sonnenfeld T; Avrahami D; Friedman-Levi Y; Gabizon R
Cell Mol Neurobiol; 2008 Nov; 28(7):1005-15. PubMed ID: 18350378
[TBL] [Abstract][Full Text] [Related]
22. Region-Specific Sialylation Pattern of Prion Strains Provides Novel Insight into Prion Neurotropism.
Makarava N; Chang JC; Baskakov IV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012886
[TBL] [Abstract][Full Text] [Related]
23. Comparative profiling of highly enriched 22L and Chandler mouse scrapie prion protein preparations.
Moore RA; Timmes A; Wilmarth PA; Priola SA
Proteomics; 2010 Aug; 10(15):2858-69. PubMed ID: 20518029
[TBL] [Abstract][Full Text] [Related]
24. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
25. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
[TBL] [Abstract][Full Text] [Related]
26. Dextran sulphate inhibits an association of prions with plasma membrane at the early phase of infection.
Fuse T; Nakagaki T; Homma T; Tange H; Yamaguchi N; Atarashi R; Ishibashi D; Nishida N
Neurosci Res; 2021 Oct; 171():34-40. PubMed ID: 33476681
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of PrP(Sc) formation in scrapie infected N2a cells by 5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine derivatives.
Koukouli F; Paspaltsis I; Salta E; Xanthopoulos K; Koini EN; Calogeropoulou T; Sklaviadis T
Prion; 2012; 6(5):470-6. PubMed ID: 22918434
[TBL] [Abstract][Full Text] [Related]
28. The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion.
Ryou C; Titlow WB; Mays CE; Bae Y; Kim S
Biomaterials; 2011 Apr; 32(11):3141-9. PubMed ID: 21288569
[TBL] [Abstract][Full Text] [Related]
29. Characterization of prion susceptibility in Neuro2a mouse neuroblastoma cell subclones.
Uryu M; Karino A; Kamihara Y; Horiuchi M
Microbiol Immunol; 2007; 51(7):661-9. PubMed ID: 17641468
[TBL] [Abstract][Full Text] [Related]
30. Conformational properties of prion strains can be transmitted to recombinant prion protein fibrils in real-time quaking-induced conversion.
Sano K; Atarashi R; Ishibashi D; Nakagaki T; Satoh K; Nishida N
J Virol; 2014 Oct; 88(20):11791-801. PubMed ID: 25078700
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory response of microglia to prions is controlled by sialylation of PrP
Srivastava S; Katorcha E; Makarava N; Barrett JP; Loane DJ; Baskakov IV
Sci Rep; 2018 Jul; 8(1):11326. PubMed ID: 30054538
[TBL] [Abstract][Full Text] [Related]
32. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
Prion; 2015; 9(5):394-403. PubMed ID: 26555211
[TBL] [Abstract][Full Text] [Related]
33. In silico strategies on prion pathogenic conversion and inhibition from PrP
Pagadala NS; Syed K; Bhat R
Expert Opin Drug Discov; 2017 Mar; 12(3):241-248. PubMed ID: 28118747
[TBL] [Abstract][Full Text] [Related]
34. Acute formation of protease-resistant prion protein does not always lead to persistent scrapie infection in vitro.
Vorberg I; Raines A; Priola SA
J Biol Chem; 2004 Jul; 279(28):29218-25. PubMed ID: 15133048
[TBL] [Abstract][Full Text] [Related]
35. Prion protein functions and dysfunction in prion diseases.
Sakudo A; Ikuta K
Curr Med Chem; 2009; 16(3):380-9. PubMed ID: 19149584
[TBL] [Abstract][Full Text] [Related]
36. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
37. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.
Bertsch U; Winklhofer KF; Hirschberger T; Bieschke J; Weber P; Hartl FU; Tavan P; Tatzelt J; Kretzschmar HA; Giese A
J Virol; 2005 Jun; 79(12):7785-91. PubMed ID: 15919931
[TBL] [Abstract][Full Text] [Related]
38. Sc237 hamster PrPSc and Sc237-derived mouse PrPSc generated by interspecies in vitro amplification exhibit distinct pathological and biochemical properties in tga20 transgenic mice.
Yoshioka M; Imamura M; Okada H; Shimozaki N; Murayama Y; Yokoyama T; Mohri S
Microbiol Immunol; 2011 May; 55(5):331-40. PubMed ID: 21362027
[TBL] [Abstract][Full Text] [Related]
39. The N-terminal, polybasic region of PrP(C) dictates the efficiency of prion propagation by binding to PrP(Sc).
Turnbaugh JA; Unterberger U; Saá P; Massignan T; Fluharty BR; Bowman FP; Miller MB; Supattapone S; Biasini E; Harris DA
J Neurosci; 2012 Jun; 32(26):8817-30. PubMed ID: 22745483
[TBL] [Abstract][Full Text] [Related]
40. Prion propagation and toxicity occur in vitro with two-phase kinetics specific to strain and neuronal type.
Hannaoui S; Maatouk L; Privat N; Levavasseur E; Faucheux BA; Haïk S
J Virol; 2013 Mar; 87(5):2535-48. PubMed ID: 23255799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
